Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA4 | P22748 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TPMT | P51580 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | INSR | P06213 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.33 |
| ▸ | TUBB | P07437 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28699193 | 0.79 | CA2 (0.46) | CA2CA4MAPTHPGDCA1 | |
| SCHEMBL1119927 | 0.74 | CA2 (0.56) | CA2CA4MAPTHPGDCA1 | |
| SCHEMBL301662 | 0.74 | HSD17B10 (0.59) | CA2CA4MAPTHPGDCA1 | |
| SCHEMBL2097204 | 0.73 | ACHE (0.54) | MAPTAPOBEC3AAPOBEC3GTUBB4ATUBB | |
| SCHEMBL10978020 | 0.73 | HPGD (0.49) | CA2CA4MAPTHPGDHSD17B10 | |
| SCHEMBL3683983 | 0.72 | CA2 (0.54) | CA2CA4MAPTHPGDCA1 | |
| SCHEMBL14639852 | 0.71 | TUBB1 (0.37) | MAPTTUBB1 | |
| SCHEMBL12702963 | 0.71 | ALDH1A1 (0.46) | MAPTHPGDTPMTLMNAHTT | |
| Hydrochloric Acid SCHEMBL28007508 | 0.71 | ACHE (0.52) | MAPTAPOBEC3AAPOBEC3GTUBB4ATUBB | |
| SCHEMBL10796412 | 0.71 | GRIN2D (0.42) | CA2CA4MAPTHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-7989462-B2 | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
| US-7618975-B2 | 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080039479-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080032974-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080004297-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| EP-1833482-A2 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| WO-2006074147-A2 | NITROGEN CONTAINING BICYCLIC COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050137213-A1 | Compounds and therapeutical use thereof | MYRIAD GENETICS, INCORPORATED (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CA2 3243/4885CA4 1823/4885MAPT 4163/4885 |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | CA2 2491/4885CA4 1516/4885MAPT 4241/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CA2 2617/4885CA4 1545/4885MAPT 4082/4885 |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CA2 3243/4885CA4 1823/4885MAPT 4163/4885 |
| US-20080032974-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CA2 3243/4885CA4 1823/4885MAPT 4163/4885 |
| US-20080004297-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CA2 3243/4885CA4 1823/4885MAPT 4163/4885 |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CA2 3243/4885CA4 1823/4885MAPT 4163/4885 |
| US-20050137213-A1 | Compounds and therapeutical use thereof | BAD, CASP3, BAX | CA2 3243/4885CA4 1823/4885MAPT 4163/4885 |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CA2 3243/4885CA4 1823/4885MAPT 4163/4885 |
| US-20080039479-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CA2 3243/4885CA4 1823/4885MAPT 4163/4885 |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | CA2 3243/4885CA4 1823/4885MAPT 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.